Any-grade treatment-emergent adverse events (AEs) occurred in 366 (98.7%) of 371 patients, with the most frequent being diarrhea (52.3%), nausea (41.5%), and fatigue (31.8%). At data cutoff, median duration of umbralisib treatment was 5.9 months (range, 0.1-75.1 months), and 107 patients (28.8%) received umbralisib for в‰Ґ12 months. This study analyzed integrated comprehensive toxicity data from 4 open-label, phase 1 and 2 studies that included 371 adult patients (median age, 67 years) with relapsed/refractory non-Hodgkin lymphoma (follicular lymphoma marginal zone lymphoma diffuse large B-cell lymphoma/mantle cell lymphoma chronic lymphocytic leukemia and other tumor types ) who were treated with the recommended phase 2 dose of umbralisib 800 mg or higher once daily. Umbralisib is a dual inhibitor of PI3KОґ and casein kinase-1Оµ (CK1Оµ). Phosphoinositide 3-kinase-Оґ (PI3KОґ) inhibitors are active in lymphoid malignancies, although associated toxicities can limit their use. 29 Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN.28 Willamette Valley Cancer Institute/US Oncology Research, Eugene, OR and.27 Swedish Cancer Institute, Seattle, WA.25 Oncology Hematology Care, Cincinnati, OH.24 Florida Cancer Specialists North/Sarah Cannon Research Institute, St.23 Sir Charles Gairdner Hospital and University of Western Australia, Perth, Australia.22 John Theurer Cancer Center, Hackensack Meridian Health School of Medicine, Hackensack, NJ.George's University of London, London, United Kingdom.

20 The Oncology Institute of Hope and Innovation, Downey, CA.

19 Rocky Mountain Cancer Centers/US Oncology Research, Aurora, CO.

18 Institute of Hematology and Transfusion Medicine, Warsaw, Poland.17 University Hospitals Seidman Cancer Center, Cleveland, OH.16 University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.15 Weill Cornell Medicine, New York, NY.14 Gdynia Oncology Center, Gdynia, Poland.13 Florida Cancer Specialists South/Sarah Cannon Research Institute, Fort Myers, FL.12 Duke University Health System, Duke Cancer Institute, Durham, NC.11 Onco-Hematology Division, European Institute of Oncology IRCCS, Department of Health Sciences, University of Milan, Milan, Italy.10 Lymphoma Research Foundation, New York, NY.9 Levine Cancer Institute, Atrium Health, Charlotte, NC.8 Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL.7 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'SerГ gnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale UniversitГ degli Studi, Bologna, Italy.6 Medical College of Wisconsin, Milwaukee, WI.4 Maria SkЕ‚odowska-Curie National Research Institute of Oncology, KrakГіw, Poland.

2 Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA.

1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Latinvfr rsw 1.1 download